References
- http://www.cancer.gov/dictionary?CdrID=44004
- Ferri N, Siegl P, Corsini A, et al. Drug attrition during pre-clinical and clinical development: understanding and managing drug-induced cardiotoxicity. Pharmacol Ther. 2013;138:470–484.
- Albini A, Pennesi G, Donatelli F, et al. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst. 2010;102:14–25.
- Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20:1215–1221.
- Fiuza M, Megalhaes A. Trastuzumab and cardiotoxicity. Rijeka, Croatia: InTech. Cardiotoxicity of oncologic treatments; 2012. 131–152. Prof Manuela Fiuza (Ed).
- Laverty H, Benson C, Cartwright E, et al. How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines? Br J Pharmacol. 2011;163:675–693.
- Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments. Nat Rev Cardiol. 2015;12:620.
- Truong J, Yan AT, Cramarossa G, et al. Chemotherapy-induced cardiotoxicity: detection, prevention, and management. Can J Cardiol. 2014;30:869–878.
- Schlitt A, Jordan K, Vordermark D, et al. Cardiotoxicity and oncological treatments. Dtsch Arztebl Int. 2014;111:161–168.
- http://www.cancer.gov/dictionary?CdrID=44916
- Raschi E, Vasina V, Ursino MG, et al. Anticancer drugs and cardiotoxicity: insights and perspectives in the era of targeted therapy. Pharmacol Ther. 2010;125:196–218.
- Simunek T, Sterba M, Popelova O, et al. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep. 2009;61:154–171.
- Chen B, Peng X, Pentassuglia L, et al. Molecular and cellular mechanisms of anthracycline cardiotoxicity. Cardiovasc Toxicol. 2007;7:114–121.
- http://www.cancer.gov/cancertopics/treatment/types/targeted-therapies/targeted-therapies-fact-sheet
- Jensen BC, McLeod HL. Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity. Pharmacogenomics. 2013;14:205–213.
- Babar T, Blomberg C, Hoffner E, et al. Anti-HER2 cancer therapy and cardiotoxicity. Curr Pharm Des. 2014;20:4911–4919.
- Guo S, Wong S. Cardiovascular toxicities from systemic breast cancer therapy. Front Oncol. 2014;4:346.
- Ewer MS, Tan-Chiu E. Reversibility of trastuzumab cardiotoxicity: is the concept alive and well? J Clin Oncol. 2007;25:5532–5533.
- Telli ML, Hunt SA, Carlson RW, et al. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol. 2007;25:3525–3533.
- Cardinale D, Colombo A, Torrisi R, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol. 2010;28:3910–3916.
- Arteaga CL, Engelman JA. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell. 2014;25:282–303.
- Elloumi J, Jellali K, Jemel I, et al. Monoclonal antibodies as cancer therapeutics. Recent Pat Biotechnol. 2012;6:45–56.
- Seshacharyulu P, Ponnusamy MP, Haridas D, et al. Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012;16:15–31.
- Warnault P, Yasri A, Coisy-Quivy M, et al. Recent advances in drug design of epidermal growth factor receptor inhibitors. Curr Med Chem. 2013;20:2043–2067.
- Sibilia M, Kroismayr R, Lichtenberger BM, et al. The epidermal growth factor receptor: from development to tumorigenesis. Differentiation. 2007;75:770–787.
- Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer. 2009;9:463–475.
- Hollmen M, Elenius K. Potential of ErbB4 antibodies for cancer therapy. Future Oncol. 2010;6:37–53.
- Hynes NE, Stern DF. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta. 1994;1198:165–184.
- Chen B, Bronson RT, Klaman LD, et al. Mice mutant for Egfr and Shp2 have defective cardiac semilunar valvulogenesis. Nat Genet. 2000;24:296–299.
- Sibilia M, Wagner EF. Strain-dependent epithelial defects in mice lacking the EGF receptor. Science. 1995;269:234–238.
- Crone SA, Zhao YY, Fan L, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med. 2002;8:459–465.
- Lee KF, Simon H, Chen H, et al. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature. 1995;378:394–398.
- Riethmacher D, Sonnenberg-Riethmacher E, Brinkmann V, et al. Severe neuropathies in mice with targeted mutations in the ErbB3 receptor. Nature. 1997;389:725–730.
- Erickson SL, O’Shea KS, Ghaboosi N, et al. ErbB3 is required for normal cerebellar and cardiac development: a comparison with ErbB2-and heregulin-deficient mice. Development. 1997;124:4999–5011.
- Gassmann M, Casagranda F, Orioli D, et al. Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature. 1995;378:390–394.
- Fuller SJ, Sivarajah K, Sugden PH. ErbB receptors, their ligands, and the consequences of their activation and inhibition in the myocardium. J Mol Cell Cardiol. 2008;44:831–854.
- Zhao YY, Sawyer DR, Baliga RR, et al. Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J Biol Chem. 1998;273:10261–10269.
- Iwamoto R, Yamazaki S, Asakura M, et al. Heparin-binding EGF-like growth factor and ErbB signaling is essential for heart function. Proc Natl Acad Sci U S A. 2003;100:3221–3226.
- De Keulenaer GW, Doggen K, Lemmens K. The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy. Circ Res. 2010;106:35–46.
- García-Rivello H, Taranda J, Said M, et al. Dilated cardiomyopathy in Erb-b4-deficient ventricular muscle. Am J Physiol Heart Circ Physiol. 2005;289:H1153–60.
- Ozcelik C, Erdmann B, Pilz B, et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci U S A. 2002;99:8880–8885.
- Pugatsch T1, Abedat S, Lotan C, et al. Anti-erbB2 treatment induces cardiotoxicity by interfering with cell survival pathways. Breast Cancer Res. 2006;8:R35.
- Campreciós G, Lorita J, Pardina E, et al. Expression, localization, and regulation of the neuregulin receptor ErbB3 in mouse heart. J Cell Physiol. 2011;226:450–455.
- Parodi EM, Kuhn B. Signalling between microvascular endothelium and cardiomyocytes through neuregulin. Cardiovasc Res. 2014;102:194–204.
- Rohrbach S, Niemann B, Silber RE, et al. Neuregulin receptors erbB2 and erbB4 in failing human myocardium – depressed expression and attenuated activation. Basic Res Cardiol. 2005;100:240–249.
- Uray IP, Connelly JH, Thomázy V, et al. Left ventricular unloading alters receptor tyrosine kinase expression in the failing human heart. J Heart Lung Transplant. 2002;21:771–782.
- Rajagopalan V1, Zucker IH, Jones JA, et al. Cardiac ErbB-1/ErbB-2 mutant expression in young adult mice leads to cardiac dysfunction. Am J Physiol Heart Circ Physiol. 2008;295:H543–54.
- www.accessdata.fda.gov/drugsatfda_docs/label/2012/125084s0228lbl.pdf
- www.accessdata.fda.gov/drugsatfda_docs/label/2015/125147s200lbl.pdf
- www.accessdata.fda.gov/drugsatfda_docs/label/2010/103792s5250lbl.pdf
- www.accessdata.fda.gov/drugsatfda_docs/label/2012/125409lbl.pdf
- www.accessdata.fda.gov/drugsatfda_docs/label/2015/125427s087lbl.pdf
- www.accessdata.fda.gov/drugsatfda_docs/label/2015/125547s000lbl.pdf
- www.accessdata.fda.gov/drugsatfda_docs/label/2010/021743s14s16lbl.pdf
- www.accessdata.fda.gov/drugsatfda_docs/label/2012/022059s013lbl.pdf
- www.accessdata.fda.gov/drugsatfda_docs/label/2003/021399lbl.pdf
- www.accessdata.fda.gov/drugsatfda_docs/label/2011/022405s000lbl.pdf
- www.accessdata.fda.gov/drugsatfda_docs/label/2016/201292s009lbl.pdf
- www.accessdata.fda.gov/drugsatfda_docs/label/2015/208065s000lbl.pdf
- Chen T, Xu T, Li Y, et al. Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis. Cancer Treat Rev. 2011;37:312–320.
- Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–792.
- Thavendiranathan P, Abdel-Qadir H, Fischer HD, et al. Breast cancer therapy-related cardiac dysfunction in adult women treated in routine clinical practice: a population-based cohort study. J Clin Oncol. 2016;34:2239–2246.
- Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomized controlled trial. Lancet. 2007;369:29–36.
- Suter TM, Procter M, Van Veldhuisen DJ, et al. Trastuzumab-associated cardiac adverse effects in the Herceptin adjuvant trial. J Oncol. 2007;25:3859–3865.
- Bria E, Cuppone F, Milella M, et al. Trastuzumab cardiotoxicity: biological hypotheses and clinical open issues. Expert Opin Biol Ther. 2008;8:1963–1971.
- Moslehi JJ. Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med. 2016;75:1457–1467.
- Wu WJ, Dokmanovic MT, Schwab M, editor. Encyclopedia of cancer: springerReference. Berlin Heidelberg, Germany: Springer-Verlag; 2009.
- Dokmanovic M, Wu WJ. Trastuzumab-resistance and breast cancer, breast cancer-carcinogenesis, cell growth and signalling pathways. 2011. Prof Mehmet Gunduz (Ed.). Rijeka, Croatia:In Tech.
- Harbeck N, Beckmann MW, Rody A, et al. HER2 dimerization inhibitor pertuzumab – mode of action and clinical data in breast cancer. Breast Care (Basel). 2013;8:49–55.
- Sendur MA, Aksoy S, Altundag K. Pertuzumab-induced cardiotoxicity: safety compared with trastuzumab. Future Oncol. 2015;11:13–15.
- Sendur MA, Aksoy S, Altundag K. Cardiotoxicity of novel HER2-targeted therapies. Curr Med Res Opin. 2013;29:1015–1024.
- Lenihan D, Suter T, Brammer M, et al. Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab. Ann Oncol. 2012;23:791–800.
- Swain SM, Kim SB, Cortés J, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013;14:461–471.
- http://hcp.novartis.com/products/tykerb/her2-abc-mbc/mechanism-of-action/
- Valachis A, Nearchou A, Polyzos NP, et al. Cardiac toxicity in breast cancer patients treated with dual HER2 blockade. Int J Cancer. 2013;133:2245–2252.
- Toema BM. A patient with metastatic colon cancer to the liver presenting with cardiac arrest status post receiving combination irinotecan-panitumumab: a case report. J Exp Ther Oncol. 2010;8(4):321–325.
- Lynch DR Jr., Kickler TS, Rade JJ. Recurrent myocardial infarction associated with gefitinib therapy. J Thromb Thrombolysis. 2011;32:120–124.
- Raschi E, De PF. Cardiovascular toxicity of anticancer-targeted therapy: emerging issues in the era of cardio-oncology. Intern Emerg Med. 2012;7:113–131.
- Negro A, Brar BK, Lee KF. Essential roles of Her2/erbB2 in cardiac development and function. Recent Prog Horm Res. 2004;59:1–12.
- Rudmann DG. On-target and off-target-based toxicologic effects. Toxicol Pathol. 2013;41:310–314.
- Rana P, Anson B, Engle S, et al. Characterization of human-induced pluripotent stem cell-derived cardiomyocytes: bioenergetics and utilization in safety screening. Toxicol Sci. 2012;130:117–131.
- Waller CF. Imatinib mesylate. Recent Results Cancer Res. 2014;201:1–25.
- Ryberg M. Cardiovascular toxicities of biological therapies. Semin Oncol. 2013;40:168–177.
- Volkova M, Russell R 3rd. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr Cardiol Rev. 2011;7:214–220.
- Singh KK, Shukla PC, Quan A, et al. Herceptin, a recombinant humanized anti-ERBB2 monoclonal antibody, induces cardiomyocyte death. Biochem Biophys Res Commun. 2011;411:421–426.
- Riccio G, Esposito G, Leoncini E, et al. Cardiotoxic effects, or lack thereof, of anti-ErbB2 immunoagents. Faseb J. 2009;23:3171–3178.
- ElZarrad MK, Mukhopadhyay P, Mohan N, et al. Trastuzumab alters the expression of genes essential for cardiac function and induces ultrastructural changes of cardiomyocytes in mice. Plos One. 2013;8(11):e79543.
- De Korte MA, De Vries EG, Lub-De Hooge MN, et al. 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity. Eur J Cancer. 2007;43:2046–2051.
- Yousif NG, Al-Amran FG. Novel Toll-like receptor-4 deficiency attenuates trastuzumab (Herceptin) induced cardiac injury in mice. BMC Cardiovasc Disord. 2011;11:62.
- Mohan N, Shen Y, Endo Y, et al. Trastuzumab, but not pertuzumab, dysregulates HER2 signaling to mediate inhibition of autophagy and increase in reactive oxygen species production in human cardiomyocytes. Mol Cancer Ther. 2016;15:1321–1331.
- Dokmanovic M, Wu Y, Shen Y, et al. Trastuzumab-induced recruitment of Csk-homologous kinase (CHK) to ErbB2 receptor is associated with ErbB2-Y1248 phosphorylation and ErbB2 degradation to mediate cell growth inhibition. Cancer Biol Ther. 2014;15:1029–1041.
- Bersell K, Arab S, Haring B, et al. Neuregulin1/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury. Cell. 2009;138:257–270.
- D’Uva G, Aharonov A, Lauriola M, et al. ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation. Nat Cell Biol. 2015;17:627–638.
- Fedele C, Riccio G, Malara AE, et al. Mechanisms of cardiotoxicity associated with ErbB2 inhibitors. Breast Cancer Res Treat. 2012;134:595–602.
- Lenneman CG, Abdallah WM, Smith HM, et al. Sympathetic nervous system alterations with HER2+ antagonism: an early marker of cardiac dysfunction with breast cancer treatment? Ecancermedicalscience. 2014;8:446.
- Rohrbach S, Yan X, Weinberg EO, et al. Neuregulin in cardiac hypertrophy in rats with aortic stenosis. Differential expression of erbB2 and erbB4 receptors. Circulation. 1999;27(100):407–412.
- Pentassuglia L, Sawyer DB. The role of neuregulin-1beta/ErbB signaling in the heart. Exp Cell Res. 2009;15(315):627–637.
- D’Avino C, Paciello R, Riccio G, et al. Effects of a second-generation human anti-ErbB2 ImmunoRNase on trastuzumab-resistant tumors and cardiac cells. Protein Eng Des Sel. 2014;27:83–88.
- Fedele C, Riccio G, Coppola C, et al. Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors. Breast Cancer Res Treat. 2012;133:511–521.
- Hasinoff BB, Patel D, Wu X. The dual-targeted HER1/HER2 tyrosine kinase inhibitor lapatinib strongly potentiates the cardiac myocyte-damaging effects of doxorubicin. Cardiovasc Toxicol. 2013;13:33–47.
- Yang B, Papoian T. Tyrosine kinase inhibitor (TKI)-induced cardiotoxicity: approaches to narrow the gaps between preclinical safety evaluation and clinical outcome. J Appl Toxicol. 2012;32:945–951.
- Force T, Kolaja KL. Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes. Nat Rev Drug Discov. 2011;10:111–126.
- Grilo NM, Charneira C, Pereira SA, et al. Bioactivation to an aldehyde metabolite – possible role in the onset of toxicity induced by the anti-HIV drug abacavir. Toxicol Lett. 2014;224:416–423.
- Hanton G. Preclinical cardiac safety assessment of drugs. Drugs R D. 2007;8:213–228.
- Hamaguchi T, Azuma J, Harada H, et al. Protective effect of taurine against doxorubicin-induced cardiotoxicity in perfused chick hearts. Pharmacol Res. 1989;21:729–734.
- Narayana Moorthy NS, Ramos MJ, Fernandes PA. Human ether-a-go-go-related gene channel blockers and its structural analysis for drug design. Curr Drug Targets. 2013;14:102–113.
- Chi KR. Revolution dawning in cardiotoxicity testing. Nat Rev Drug Discov. 2013;12:565–567.
- Chi KR. Regulatory watch: speedy validation sought for new cardiotoxicity testing strategy. Nat Rev Drug Discov. 2013;12:655.
- Sager PT, Gintant G, Turner JR, et al. Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the Cardiac Safety Research Consortium. Am Heart J. 2014;167:292–300.
- Wisniowska B, Mendyk A, Fijorek K, et al. Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment. J Appl Toxicol. 2012;32:858–866.
- Wisniowska B, Mendyk A, Szlek J, et al. Enhanced QSAR models for drug-triggered inhibition of the main cardiac ion currents. J Appl Toxicol. 2015;35:1030–1039.
- Limberis JT, Su Z, Cox BF, et al. Altering extracellular potassium concentration does not modulate drug block of human ether-a-go-go-related gene (hERG) channels. Clin Exp Pharmacol Physiol. 2006;33:1059–1065.
- Mirams GR, Cui Y, Sher A, et al. Simulation of multiple ion channel block provides improved early prediction of compounds’ clinical torsadogenic risk. Cardiovasc Res. 2011;91:53–61.
- Hoekstra M, Mummery CL, Wilde AA, et al. Induced pluripotent stem cell derived cardiomyocytes as models for cardiac arrhythmias. Front Physiol. 2012;3:346.
- Christenson ES, James T, Agrawal V, et al. Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity. Clin Biochem. 2015;48:223–235.
- Kinova E, Goudev A. Early detection and prediction of cardiotoxicity – biomarker and echocardiographic evaluation, cardiotoxicity of oncologic treatments. 2012. Fiuza M (Ed), editor. Rijeka, Croatia:In Tech.
- Tian S, Hirshfield KM, Jabbour SK, et al. Serum biomarkers for the detection of cardiac toxicity after chemotherapy and radiation therapy in breast cancer patients. Front Oncol. 2014;4:277.
- Milano G, Raucci A, Scopece A, et al. Doxorubicin and trastuzumab regimen induces biventricular failure in mice. J Am Soc Echocardiogr. 2014;27:568–579.
- Babuin L, Jaffe AS. Troponin: the biomarker of choice for the detection of cardiac injury. Cmaj. 2005;173:1191–1202.
- Fallah-Rad N, Walker JR, Wassef A, et al. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy. J Am Coll Cardiol. 2011;57:2263–2270.
- Stanton SE, Ward MM, Christos P, et al. Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity. BMC Cancer. 2015;15:267.
- Beauclair S, Formento P, Fischel JL, et al. Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity. Ann Oncol. 2007;18:1335–1341.
- Milano GA, Serres E, Ferrero JM, et al. Trastuzumab-induced cardiotoxicity: is it a personalized risk? Curr Drug Targets. 2014;15:1200–1204.
- Dokmanovic M, Wu WJ. Monitoring trastuzumab resistance and cardiotoxicity: a tale of personalized medicine. Adv Clin Chem. 2015;70:95–130.
- Ewer MS, Gibbs HR, Swafford J, et al. Cardiotoxicity in patients receiving trastuzumab (Herceptin): primary toxicity, synergistic or sequential stress, or surveillance artifact? Semin Oncol. 1999;26:96–101.
- Jerian S, Keegan P. Cardiotoxicity associated with paclitaxel/trastuzumab combination therapy. J Clin Oncol. 1999;17:1647–1648.
- Bowles EJ, Wellman R, Feigelson HS, et al. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst. 2012;104:1293–1305.
- https://clinicaltrials.gov
- Reichert JM, Dhimolea E. The future of antibodies as cancer drugs. Drug Discov Today. 2012;17:954–963.
- Cohen RB. Current challenges and clinical investigations of epidermal growth factor receptor (egfr)- and erbb family-targeted agents in the treatment of head and neck squamous cell carcinoma (hnscc). Cancer Treat Rev. 2014;40:567–577.
- Machiels JP, Specenier P, Krauss J, et al. A proof of concept trial of the anti-EGFR antibody mixture Sym004 in patients with squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol. 2015;76:13–20.
- Rihawi K, Giampieri R, Scartozzi M, et al. Role and mechanisms of resistance of epidermal growth factor receptor antagonists in the treatment of colorectal cancer. Expert Opin Investig Drugs. 2015;24: 1185–1198.
- Fayette J, Wirth L, Oprean C, et al. Randomized phase II study of duligotuzumab (MEHD7945A) vs. cetuximab in aquamous cell carcinoma of the head and neck (MEHGAN study). Front Oncol. 2016;6:232
- Bang YJ, Giaccone G, Im SA, et al. First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors. Ann Oncol. 2017;28:855–861.
- https://clinicaltrials.gov/ct2/show/NCT02052960
- Reichert JM. Antibodies to watch in 2015. MAbs. 2015;7:1–8.
- https://clinicaltrials.gov/ct2/show/NCT01304784
- Kiewe P, Hasmuller S, Kahlert S, et al. Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer. Clin Cancer Res. 2006;12:3085–3091.
- Kim SH, Shim HS, Cho J, et al. A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC). Lung Cancer. 2013;79:270–275.
- Satoh T, Lee KH, Rha SY, et al. Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer. Gastric Cancer. 2015;18:824–832.
- Strumberg D, Schultheis B, Scheulen ME, et al. Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer. Invest New Drugs. 2012;30:1138–1143.
- Jiang N, Wang D, Hu Z, et al. Combination of anti-HER3 antibody MM-121/SAR256212 and cetuximab inhibits tumor growth in preclinical models of head and neck squamous cell carcinoma. Mol Cancer Ther. 2014:13:1826–1836.
- Machiels JP, Subramanian S, Ruzsa A, et al. Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial. Lancet Oncol. 2011;12:333–343.
- Shi Y, Zhang L, Liu X, et al. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. Lancet Oncol. 2013;14:953–961.
- Reardon DA, Conrad CA, Cloughesy T, et al. Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients. Cancer Chemother Pharmacol. 2012;69:1507–1518.
- Soria JC, Baselga J, Hanna N, et al. Phase I-IIa study of BMS-690514, an EGFR, HER-2 and −4 and VEGFR-1 to −3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours. Eur J Cancer. 2013;49:1815–1824.
- Pietanza MC, Gadgeel SM, Dowlati A, et al. Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer. J Thorac Oncol. 2012;7:856–865.
- Janne PA, Ou SH, Kim DW, et al. Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2014;15:1433–1441.
- Bryce AH, Rao R, Sarkaria J, et al. Phase I study of temsirolimus in combination with EKB-569 in patients with advanced solid tumors. Invest New Drugs. 2012;30:1934–1941.
- Saura C, Garcia-Saenz JA, Xu B, et al. Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2014;32:3626–3633.
- Martin M, Bonneterre J, Geyer CE Jr., et al. A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer. Eur J Cancer. 2013;49:3763–3772.
- Rixe O, Franco SX, Yardley DA, et al. A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer. Cancer Chemother Pharmacol. 2009;64:1139–1148.